Corona vir\u00fcs\u00fcn\u00fcn alt varyantlar\u0131na kar\u015f\u0131 etkili olacak a\u015f\u0131lar\u0131n sonbaharda haz\u0131r olmas\u0131 bekleniyor.<\/p>\n
Deutsche Welle T\u00fcrk\u00e7e\u2019nin Alman Doktorlar Gazetesi\u2019ne dayand\u0131rd\u0131\u011f\u0131 habere g\u00f6re Alman biyoteknoloji firmas\u0131 BioNTech, alt varyantlara kar\u015f\u0131 etkili olacak a\u015f\u0131s\u0131n\u0131 resmi onaylara ba\u011fl\u0131 olarak Avrupa\u2019da Eyl\u00fcl ay\u0131nda teslim etmeyi planlad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/p>\n
BioNTech ve ABD\u2019li Pfizer \u015firketinin, Omicron varyant\u0131n\u0131n alt varyant\u0131 XXB.1,5\u2019ye kar\u015f\u0131 a\u015f\u0131 geli\u015ftirdi\u011fi a\u00e7\u0131kland\u0131. Almanya ve Avrupa\u2019n\u0131n bir\u00e7ok \u00fclkesinde giderek yay\u0131lan yeni varyant EG.5\u2019in de XBB\u2019den t\u00fcredi\u011fi belirtiliyor.<\/p>\n
ABD\u2019li Moderna firmas\u0131 da gazeteye yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, geli\u015ftirdi\u011fi a\u015f\u0131n\u0131n sonbahara yeti\u015fece\u011fi mesaj\u0131n\u0131 verdi ve onay almas\u0131n\u0131n ard\u0131ndan piyasaya s\u00fcr\u00fclece\u011fini kaydetti. Bunun yan\u0131 s\u0131ra ABD\u2019li Novavax firmas\u0131 da ayn\u0131 \u015fekilde Omicron\u2019un alt varyant\u0131na kar\u015f\u0131 etkili olacak bir a\u015f\u0131 \u00fczerinde \u00e7al\u0131\u015f\u0131yor.<\/p>\n
Gazeteye g\u00f6re yeni a\u015f\u0131lar\u0131n kullan\u0131m\u0131n\u0131n daha kolay olmas\u0131 planlan\u0131yor. Biyoteknoloji \u015firketleri \u00f6ncelikle a\u015f\u0131lar\u0131 tek dozluk \u015fekilde \u00fcretecek. Daha \u00f6ncesinde a\u015f\u0131lar birka\u00e7 dozluk olarak \u00fcretiliyor ve a\u00e7\u0131lmalar\u0131 halinde k\u0131sa s\u00fcre i\u00e7inde kullan\u0131lmalar\u0131 gerekiyordu.<\/p>\n
U\u011eUR \u015eAH\u0130N\u2019DEN TEPK\u0130<\/strong><\/p>\n BioNTech\u2019in kurucusu U\u011fur \u015eahin Frankfurter Allgemeine Zeitung\u2019a yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, yeni ila\u00e7lar geli\u015ftirilirken onay s\u00fcrecindeki verimsiz ve uzun prosed\u00fcr\u00fc ele\u015ftirdi.<\/p>\n \u0130lk a\u015f\u0131 geli\u015ftirilirken yetkili birimlerle yap\u0131lan yo\u011fun i\u015fbirli\u011fine dikkat \u00e7eken \u015eahin, \u201c\u015eimdi yeniden normale d\u00f6nd\u00fck ve bu yine uzun bir i\u015flem s\u00fcreci anlam\u0131na geliyor. Almanya ve Avrupa\u2019da \u00e7ok yetkin d\u00fczenleyici birimler var. Ama hem yetkili makamlar, hem de ila\u00e7 geli\u015ftiricilerinin kaynaklar\u0131n\u0131 b\u00fcy\u00fck oranda t\u00fcketen verimsiz bir s\u00fcre\u00e7 var\u201d diye konu\u015ftu.<\/p>\n \u015eahin, teknolojik olanaklarla b\u00fcrokrasinin izin verdikleri aras\u0131nda bir uyumsuzluk oldu\u011funu s\u00f6yleyerek \u201cBunun nedeni gereksiz b\u00fcrokrasi. Bir di\u011fer eksiklikse i\u015flem s\u00fcrelerini uzatan kaynak eksikli\u011fi\u201d dedi. \u015eahin ilac\u0131n \u00e7ok \u00f6nemli oldu\u011funu belirterek, \u201cSistemin tembelli\u011fi onaylar\u0131 geciktiren bir darbo\u011faz olmamal\u0131\u201d ifadesini kulland\u0131.<\/p>\n Avrupa Birli\u011fi\u2019nde (AB) ila\u00e7 ya da a\u015f\u0131lar\u0131n onay alma s\u00fcreci birka\u00e7 a\u015famadan olu\u015fuyor. Bu a\u015famalar aras\u0131nda \u00e7ok say\u0131da klinik ara\u015ft\u0131rmas\u0131n\u0131n yap\u0131lmas\u0131 ko\u015fulu da bulunuyor. Bu a\u015famalar\u0131n sonucunda Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) s\u00f6z konusu ila\u00e7 ya da a\u015f\u0131ya dair g\u00f6r\u00fc\u015f\u00fcn\u00fc a\u00e7\u0131kl\u0131yor ve Avrupa Birli\u011fi Komisyonu da onay konusunda karar\u0131n\u0131 a\u00e7\u0131kl\u0131yor. AB Komisyonu gelecekte onay s\u00fcrecindeki son iki a\u015fama i\u00e7in belirlenen s\u00fcrenin k\u0131salt\u0131labilece\u011fini duyurmu\u015ftu.<\/p>\n","protected":false},"excerpt":{"rendered":" Corona vir\u00fcs\u00fcn\u00fcn endi\u015fe yaratan alt varyantlar\u0131na kar\u015f\u0131 geli\u015ftirilen yeni a\u015f\u0131lar\u0131n sonbaharda piyasaya s\u00fcr\u00fclmesi planlan\u0131yor. BioNTech kurucusu U\u011fur \u015eahin ise a\u015f\u0131n\u0131n onay s\u00fcrecini ele\u015ftirdi.<\/p>\n","protected":false},"author":1,"featured_media":116429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[3368,180,253,1182,86],"class_list":["post-116428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-alma","tag-asi","tag-avrupa","tag-onay","tag-sure"],"_links":{"self":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/116428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=116428"}],"version-history":[{"count":1,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/116428\/revisions"}],"predecessor-version":[{"id":116430,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/116428\/revisions\/116430"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/media\/116429"}],"wp:attachment":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=116428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=116428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=116428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}